1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNIDA Funding Opportunities (Various Programs) is sponsored by National Institute on Drug Abuse (NIDA). NIDA offers various funding opportunities to support basic and clinical research addressing substance use disorders.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NIH Websites Are Changing NIH Websites Are Changing Learn more in our Frequently Asked Questions . As of October 2025, the NIDA Funding App has been retired. The NIH announcement stating this change can be read here: NOT-OD-25-143 .
NIDA Funding Strategy – A review of NIDA’s strategy for funding, based on programmatic priorities. Notice of Special Interest (NOSI) - Formerly known as Drug Abuse Topics of Special/Continuing Interest (DAT) NIDA Challenges Program – Crowd-sourced opportunities for providing solutions for particular goals. Helping to End Addiction Long-term (HEAL) Initiative – Congressional initiative to address the opioid overdose crisis.
NIDA International Program – International research collaboration opportunities on drug abuse and addiction. See NIDA’s Resources for Grants & Contracts to learn more about applying for a grant and the pre-approval and approval process. Administrative Supplements for Grants & Cooperative Agreements Administrative Supplements for Grants & Cooperative Agreements – Additional funding to an active NIDA grant or cooperative agreement.
Supplemental Information for NOFOs Supplemental Information for NOT-DA-22-064: Notice of Intent to Publish a Funding Opportunity Announcement for NIH Brain Development Cohorts Biospecimen Access FAQs for Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders - RFA-DA-24-007.
FAQs for Registry of Medical Cannabis Use and Health Outcomes: RFA-DA-23-011 Supplemental Information for NIH Developmental Studies Biospecimen Access Program FAQs for Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders - RFA-DA-23-014 Pre-Application Information Webinar for PAR-21-183, "Developing Digital Therapeutics for Substance Use Disorders FAQs Regarding Notice of Information: Establishment of a Standard THC Unit to be Used in Research (NOT-DA-21-049) Frequently Asked Questions about NOT-DA-21-041: Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus RFA-DA-21-009: Pre-Application Webinar and FAQs- Interventions to Prevent Electronic Nicotine Delivery Systems (ENDS) Use Among Adolescents Step Up for Substance Use Disorders (SUD): A Drug Target Initiative for Scientists Engaged in Fundamental Research - RFA-DA-20-025 FAQs for Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1) FAQs for NOT-DA-19-003: HEAL Initiative: Request for Administrative Supplements to Existing Grants to Accelerate Research on Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 16-30) Supplemental Information (FAQs) for NIDA Research E-cigarette - PAR-17-156 Supplemental Information (FAQs) for RFA-DA-17-014 and RFA-DA-17-023
According to the current listing, eligibility includes: Eligibility varies by specific funding opportunity. Confirm the full requirements in the official notice before applying.
The current listing shows varies by program (e.g., up to $400,000 for Phase I SBIR/STTR and $3,000,000 for Phase II). Verify award ceilings, matching requirements, and allowable costs in the official notice.
NIDA Funding Opportunities (Various Programs) is funded by National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article